Okwin Inc. is leading a consortium of hospitals and pathology labs from across France as part of a €33 million (US$36 million) project to develop and deploy new digital pathology artificial intelligence (AI) tools to improve cancer care. The project, called Portrait, is backed by the French government, and the hope is that by producing more efficient and accessible diagnostic tools, clinicians will be able to better tailor treatments to individual patients at an earlier stage of the disease.
Accyourate Group S.p.A has stepped up the commercialization of its e-shirt, a 100% textile smart T-shirt which enables continuous real-time monitoring of biomedical and vital body signals. Accyourate joins a host of companies releasing products in the wearable device market as different technologies for health care including heart rate monitoring, fitness, breathing, temperature levels and fall detection get more sophisticated and grow in popularity.
The granting of breakthrough device designation from the U.S. FDA to Pixium Vision SA for its Prima system was a boon for the company as its share price jumped more than 300% following the news. The price increase was “validation from the public market and investors” that the Prima system, for dry age-related macular degeneration (AMD), has the potential to get regulatory approval, Lloyd Diamond, CEO of Pixium, told BioWorld.
As artificial intelligence becomes more central to clinical radiology workflows, Deepc GmbH will use the €12 million (US$13 million) it recently raised in its series A round to develop additional features within its Deepcos radiology artificial intelligence (AI) platform to allow for faster and more accurate diagnoses.
Ciliatech SAS reported positive news for people suffering from glaucoma who want to avoid the complications that come with using existing glaucoma procedures. Results from the SAFARI 1 clinical trial, using its first-generation cilio-scleral inter-positioning device (CID) implant in patients with open angle glaucoma, showed marked stability of intraocular pressure (IOP), along with a significantly reduced need for glaucoma medication 24 months on from surgery.
The U.S. FDA granted Graymatters Health Ltd. 510(k) clearance to market Prism for PTSD, a non-invasive, self-neuromodulation adjunct digital therapy for post-traumatic stress disorder (PTSD).
Sofinnova Partners launched a new investment strategy focused on digital medicine in a sign that investment in European startups, especially those at the intersection of biology, data and computation is returning. “It cannot be stressed enough that there is a need in the market for this,” said Edward Kliphuis, partner in the Sofinnova Digital Medicine Strategy.
Startup Aiomic ApS received a capital injection in the form of a €1.3 million (US$1.4 million) convertible loan from Denmark’s Bioinnovation Institute (BII) that will allow the company to further develop and commercialize its artificial intelligence (AI)-driven Aiomic360 platform, which is designed to reduce the number of postoperative complications.
Mvision AI Oy raised €5.4 million (US$5.8 million) in a post seed funding round to help accelerate the development of its artificial intelligence (AI)-powered automatic segmentation software, which automates and standardizes radiotherapy treatment for patients. Mvision aims to make same day cancer treatment a standard globally. The funding was led by J12 Ventures and Voima Ventures.
Surgvision GmbH received U.S. FDA 510(k) clearance for the Explorer Air II which will be deployed with pafolacianine, during intraoperative fluorescence imaging. The Explorer Air II will support surgeons in their battle to fight cancer, especially in cases of incomplete resection, as paired with pafolacianine, an imaging agent, it will help them improve tumor visualization and outcomes.
